ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0249

Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease

Jill Poole1, Bryant England1, Kathryn Cole1, James Talmadge1, Amy Nelson1, Rohit Gaurav1, Aaron Schwabb1, Angela Gleason1, Michael Duryee1, Rhonda Walenz1, Bridget Kramer1, Joel VanDeGraaff1, Sara May1, Geoffrey Thiele1 and Ted Mikuls2, 1University of Nebraska Medical Center, Omaha, NE, 2Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE

Meeting: ACR Convergence 2022

Keywords: interstitial lung disease, Monocytes/macrophages, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Interstitial lung disease (ILD) is associated with significant morbidity and mortality in rheumatoid arthritis (RA). The key cellular players of RA-ILD remain largely unknown. Alterations in monocyte subpopulations marked by a shift from classical to intermediate and nonclassical monocytes are associated with RA. There is little information regarding monocytic-myeloid derived suppressor cells (mMDSCs) and polymorphonuclear (PMN)-MDSCs in RA, and the studies that have been reported are conflicting. Additionally, there is little to no information on these inflammatory and/or suppressive cell populations in patients with RA-ILD. Thus, the purpose of this on-going study is to characterize peripheral blood myeloid cell subpopulations in RA and RA-ILD.

Methods: Peripheral blood collected from patients with RA (N=10, all RA fulfilled ACR classification criteria), RA-ILD (N=6, all ILD based upon clinical diagnosis and CT findings), and a convenience sample of comparator patients (N=7, without autoimmune or systemic inflammatory disease) was processed and immunophenotyped for myeloid cell subpopulations by flow cytometry on the same day as collection. After removal of debris and doublets, all myeloid cell populations were gated on live, CD45+, lineage (CD3, CD19, CD56) negative, and CD11b+ cells. Monocytes, PMNs, eosinophils, and MDSCs were delineated by expression of HLA-DR, CD14, CD16, CD15, CD33 (see Table 1). Subpopulation frequency is reported as a percentage of total CD45+ cells or of parent population (monocytes) and significant differences across groups were determined by one-way ANOVA and Tukey’s post-test.

Results: The frequency and differences of the myeloid cell subpopulations across groups are shown in Table 1. Although total peripheral blood monocyte frequency did not differ across groups, we observed a significantly higher frequency of intermediate monocytes in RA and RA-ILD patients vs. control with the highest frequency observed in RA-ILD. In contrast, classical monocytes were significantly lower in patients with RA-ILD vs. both RA and control groups. Although non-significant, increased trends were observed for non-classical monocytes in RA-ILD patients. Eosinophils were significantly higher in RA-ILD vs. controls. Although there was no difference in PMNs across groups, PMN-MDSCs were significantly increased in RA-ILD vs. control groups. The frequency of mMDSCs was significantly higher in RA-ILD vs. both control and RA. Furthermore, the ratio of %monocytes to %mMDSCs differed across groups with a striking shift towards higher mMDSCs vs. monocytes in RA-ILD (Figure 1).

Conclusion: Flow cytometry-based myeloid cell immunophenotyping in patients with RA-ILD may provide comprehensive information on immune cell networks that could provide foundation for a better understanding of disease pathogenesis and more effective management. Our early preliminary results of this ongoing study suggest significant shifts in monocytic cell subpopulations with increases in intermediate/non-classical monocytes and monocytic-MDSCs as well as increases in PMN-MDSCs and eosinophils in RA-ILD, shifts that are distinct from RA alone.

Supporting image 1

Supporting image 2


Disclosures: J. Poole, AstraZeneca; B. England, Boehringer-Ingelheim; K. Cole, None; J. Talmadge, None; A. Nelson, None; R. Gaurav, None; A. Schwabb, None; A. Gleason, None; M. Duryee, None; R. Walenz, None; B. Kramer, None; J. VanDeGraaff, None; S. May, None; G. Thiele, None; T. Mikuls, Gilead Sciences, Bristol-Myers Squibb, Horizon, Sanofi, Pfizer Inc.

To cite this abstract in AMA style:

Poole J, England B, Cole K, Talmadge J, Nelson A, Gaurav R, Schwabb A, Gleason A, Duryee M, Walenz R, Kramer B, VanDeGraaff J, May S, Thiele G, Mikuls T. Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/identification-of-distinct-peripheral-blood-myeloid-cell-subpopulations-in-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-distinct-peripheral-blood-myeloid-cell-subpopulations-in-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology